Stoke Therapeutics, Inc. (NASDAQ:STOK) Director Edward M. Md Kaye Sells 10,382 Shares of Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) Director Edward M. Md Kaye sold 10,382 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the transaction, the director now directly owns 148,253 shares in the company, valued at $1,285,353.51. This represents a 6.54 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Stoke Therapeutics Trading Up 0.8 %

STOK opened at $8.33 on Friday. Stoke Therapeutics, Inc. has a 12 month low of $5.80 and a 12 month high of $17.58. The stock has a fifty day moving average price of $9.49 and a 200-day moving average price of $11.49. The firm has a market cap of $441.22 million, a price-to-earnings ratio of -3.97 and a beta of 0.99.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The business had revenue of $22.61 million during the quarter, compared to analyst estimates of $4.20 million. On average, equities research analysts forecast that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on STOK. HC Wainwright restated a “buy” rating and issued a $47.00 target price on shares of Stoke Therapeutics in a research note on Wednesday. Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research report on Tuesday. Finally, Chardan Capital reissued a “buy” rating and set a $24.00 price target on shares of Stoke Therapeutics in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $23.00.

Institutional Investors Weigh In On Stoke Therapeutics

Several institutional investors have recently bought and sold shares of STOK. Barclays PLC boosted its position in shares of Stoke Therapeutics by 145.3% in the 3rd quarter. Barclays PLC now owns 79,740 shares of the company’s stock worth $980,000 after purchasing an additional 47,239 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Stoke Therapeutics by 9.7% in the third quarter. Geode Capital Management LLC now owns 870,831 shares of the company’s stock worth $10,705,000 after acquiring an additional 76,661 shares in the last quarter. State Street Corp increased its holdings in shares of Stoke Therapeutics by 8.6% during the third quarter. State Street Corp now owns 1,728,888 shares of the company’s stock valued at $21,248,000 after acquiring an additional 137,145 shares in the last quarter. RTW Investments LP increased its holdings in shares of Stoke Therapeutics by 10.1% during the third quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock valued at $57,177,000 after acquiring an additional 427,447 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its position in shares of Stoke Therapeutics by 1,589.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company’s stock valued at $936,000 after purchasing an additional 71,647 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.